Purpose: To evaluate late physical and psychosocial sequelae in patients treated with an association of external beam irradiation (EBI) and brachytherapy (BT) for localized prostate cancer.
Background
Prostate cancer has become an important public health preoccupation. It represents the second cause of death due to cancer in the French male population and its standardized (European) incidence rate was estimated to be 92.1 per 100,000 inhabitants in France in 1995, with 26,474 new cases. The incidence rate was 27.37 oflOO.OOO in 1975 and 51.82 of 100,000 in 1985. This increase is probably the result of a higher proportion of patients screened together with an increase in the mean age of the population [1] [2] [3] .
At diagnosis, more than 60% of patients present with clinically localized disease. Although several consensus conferences have been developed, there is no agreement on localized prostate cancer treatment which can include radical prostatectomy, radiation therapy and watchful waiting [4, 5] . Surgery and radiotherapy are considered aggressive treatments inducing high cure rates but persistent patient quality of life impairment [6] . The conventional irradiation technique consists of external beam irradiation (EBI). An alternative to exclusive EBI is the association of EBI and brachytherapy (BT) as a boost according to some authors [7] [8] [9] [10] . The combination of EBI and BT is used to deliver a high dose to cancer tissue with a sharp gradient beyond the target volume [9] [10] [11] [12] . Theoretically, with this technique, less irradiation dose is delivered to critical tissue such as the rectum.
In patients with localized disease, all available studies have concerned complications and/or quality of life of patients treated with radical prostatectomy or with exclusive EBI. The main early sequelae reported by physicans concerning these patients are: sexual dysfunction, urinary incontinence and digestive complications; in contrast, long-term health-related quality of life and social impact of treatments have rarely been considered [6, [13] [14] [15] [16] [17] [18] . In these studies, when late physical and psychosocial complications were dealt with, they were generally reported by physicians. When evaluated by both patients and physicians, their appraisal largely differed [19, 20] . Morever, these studies often included patients with limited follow-up [21, 22] and most of them were not comparative [14] .
At the Centre Francois Baclesse, a regional Comprehensive Cancer Centre, most patients with localized prostate cancer are treated with EBI and BTas a boost [9] , a technique for which quality of life and sequelae reported by patients themselves have never been evaluated. A casecontrol study was therefore designed aiming at evaluating the late physical and psychosocial sequelae related to that particular irradiation technique using self-administered quality of life questionnaires, and to compare patient results to those of a healthy population. Among the 83 eligible patients, 71 (87%) agreed to participate. The non participation of the other 12 (13%) eligible patients was due to the following: death occurring during the study period (n = 2), hospilalization for orthopedic intervention (n = 1). questionnaires received after the study was closed (n = 3), and lost to follow-up (n = 6).
Patients and methods

Subjects and treatment
Selection of patients
Treatment. All selected patients were treated with a combination of external beam pelvic irradiation followed or preceded by a boost of BT limited to the prostate volume. EBI delivered 43.2 Gy to the pelvis in 4.5 weeks and 18 fractions. BT delivered 15 Gy to the prostate volume using four temporary iridium transperineal implants. Conformal planning of transperineal implant technique was based on the actual anatomy of the prostate determined by computed lomography [9] . Dosimelry was performed before and after implantation. Most patients (85%) were treated with low dose rate irradiation, 6-12 Gy per 24 hours continously. The remaining 15% patients were treated with high-dose rate irradiation, 9.4 Gy in two fractions at a 48-hour interval.
Selection of controls
A population-based comparison sample of 166 men was randomly selected from Calvados electoral rolls. Assuming a participation rate of 50%. two controls were selected and matched for one patient on age (± five years), and city of residence at the time of interview. Among the 166 controls selected, 100 (60%) participated spontaneously. Among these, nine (9%) were later lo be excluded due to previous history of prostate disease (five adenomas and four adenocarcinomas). Of the 66 non-responders, three refused to participate, five died, ten were lost to follow-up and 48 did not reply. When two controls were available for one patient, one was selected at random. The study population consisted therefore of 71 patients and 71 controls. The third questionnaire used was the prostate specific module developed by the EORTC Genito-Urinary Tract Cancer Cooperative Group which covers sexual and urinary items.
Measures
After testing on six independent patients, six complementary questions on urinary incontinence, nocturia and specific digestive symptoms, such as rectal bleeding and bowel urgency, were added to the aforementioned questionnaires. Nocluria was considered present when the patient or his control expressed more than two urinations during the night.
When a question referred to the patient's status before the disease developed, for controls it referred lo 1991 or earlier.
The three self-administered questionnaires were usually completed within 30 minutes.
Statistical analysis
Tests used for comparison of means included the Student test and the Mann-Whitney test; those used for proportion comparisons were the Chi-square test and the Fisher exact test. The linear regression model was used to test the correlation that exists between general quality of life scores and those issued from the prostate module. Multivariate analysis of variance and covariance (ANCOVA) was used for groupwise comparisons of the NHP scores and EORTC QLQ-C30 scores in which comorbid medical illnesses were covariates. Because of multiple comparisons, only results statistically significant at P level $0.01 were considered. Missing data were exceptional in patients as well as in controls. Questions concerning urinary and digestive complications were omitted for five patients by mistake; because the omission was Table 1 . Patient characteristics at time of radiation therapy (n = 71). 
Results
Patient characteristics-
Main patient clinical characteristics are listed in Table 1 . Eighty-three percent of patients had previous medical history (with high blood pressure in 31% of patients, vascular disease in 38%, digestive disease in 28%). Thirty-three percent of patients underwent abdominal surgery before the cancer developed. At diagnosis, 92% of patients presented with T2-T3 a stage. Seventeen percent of patients had transuretral resection. Pathologic grade was well-differenciated (Gleason 1-4) or moderately differenciated (Gleason 5-7) in 85% (45 of 53) of patients. Before treatment, performance status (PS) was scored as good (PS 0-1: 82%; PS 2: 18%) according to ECOG definition [28] . All patients were given EBI and BT. One third of patients were treated with EBI followed by BT; the other two thirds were given BT prior to EBI. External irradiation dose ranged between 40-45 Gy in 98% of patients. In this series, while pelvis was irradiated in 92% of cases, paraaortic nodes were never irradiated. Whatever the therapeutic plan used, BT always delivered 15 Gv. 
Sequelae reported by patients
As mentioned above, the patient's point of view was recorded using three self-administered questionnaires. Sequelae were reported more often by patients than by physicians. Dysuria was reported by 32% (21 of 65) of patients; it was considered severe by six out of the 65 patients (9%). Urinary incontinence was reported by 40% (26 of 65) of patients and was considered invalidating by six (9%) and mictionnal burning of mild intensity was expressed by 27% (17 of 64) of patients. Digestive complications were reported by 21% (13 of 63) of patients including one patient with severe rectal bleeding. Altogether, severe urinary and digestive complications were limited (Table 2) . Overall, 58 patients reported to have sexual activity before the disease developed. Of these, 71% reported a major decrease in sexual activity since treatment and 55% reported less interest in sex. At the time of the study, 35 (60%) patients were sexually active and 23 (40%) patients had stopped any sexual activity since the beginning of therapy because of impotency, independently of their marital status. Among the 35 sexually active patients, 89% reported difficulty in establishing and maintaining an erection.
Sequelae reported by physicians
At diagnosis, physicians reported dysuria in 49% (scored as severe in 5%) of patients and nocturia in 76% of patients. Urinary incontinence was mentioned in 11% (eight patients) of medical charts, whereas the use of pads was never reported. Transient haematuria (five patients) and haemospermia (one patient) were unusual. Abdominal pain was noticed in 6% (four patients) of medical charts. Before treatment, information on sexual life was available for 57 patients. Of these, 25 (44%) men had partial or complete impotency.
At last examination, dysuria was noticed in 27% of medical charts. Twenty-two percent of patients had uri- nary dripping when making an effort, 3% (two patients) had dripping with full bladder. Daily urinary dripping was noticed in 12% of patients and necessitated the use of pads in one patient only. In 90% of patients, no temporal modification of urinary incontinence was reported. Among patients with pretherapeutic dysuria, total regression was noticed in 66% (23 of 35) whilst impairement in 3% (1 of 35). Among patients without pretherapeutic dysuria, 19% (7 of 36) had mild dysuria. Among patients with pretherapeutic nocturia, improvement was noticed in 56% (30 of 54) and impairement in 5% (3 of 54). Few digestive complications were reported. There was moderate abdominal pain in five patients, diarrheoa of mild intensity in 11 patients, and rectal bleeding in seven patients (mild in six, severe necessitating surgery in one). Data on sexual function before and at the time of interview was available in 76% of medical charts. Impaired sexual activity was noticed in 30% (16 of 54) of patients, and 68% (37 of 54) had partial or complete impotency. While the frequency of dysuria was equally reported by physicians and patients, its severity was underestimated by physicians in 53% of cases. Physicians reported nocturia more often than patients (36% and 15%, respectively; P = 0.0016). In contrast, patients reported urinary incontinence more often than physicians (40% and 12%, respectively; P < 0.001). Similarly, patients reported pelvic pain more often than physicians (38% and 5%, respectively; P < 0.001). Comparison of sexuality appraisal was not carried out because information was missing in a substantial proportion of medical charts.
Case-control study
The sociodemographic characteristics of patients and controls were similar (Table 3) . Patients had medical history more frequently than controls (83% and 63%, P = 0.009); however, the type of medical history was similar in the two groups, and concerned essentially high blood pressure (40%) and vascular or cardiac diseases (60%). Satisfaction with medical care in general was significantly higher in patients than in controls with scores being 88.3 and 66.8, respectively (P -0.003).
Results from the self-reported general health status EORTC QLQ C-30 core questionnaire and those from the NHP questionnaire are reported in Table 4 . General health quality of life scale scores did not significantly differ between patients and controls, nor did general symptom scale scores. Furthermore, patients did not report more late psychosocial sequelae than controls.
In contrast, significant group differences between patients and controls were observed in prostate-targeted urinary, digestive, and sexual scale scores (Table 5 ). These differences mainly concerned urinary incontinence and mictionnal burning, with higher scores in patients than in controls (P < 0.001 and P -0.01, respectively). Digestive-related scale scores were of the same magnitude in the two groups, except for rectal bleeding that were more often reported by patients.
As far as sexuality was concerned, statistically significant differences were observed between patients who were sexually active before the treatment and controls who expressed having sexual activity four years or more before the study; these differences concerned interest in sex (P = 0.016) and sexual activity (P < 0.001) which had undergone more significant changes in patients than in controls. However, patients and controls who ex- pressed sexual activity at the time of the study had similar scale scores concerning erection and pleasure.
Finally, in patients with prostate cancer, global health status (EORTC QLQ-C30) as well as social functioning (EORTC QLQ-C30 and NHP) scale scores highly correlated with those of all of the items included in urinary status (incontinence, dysuria, mictionnal burning) (P < 0.001) but not with sexual status. The other dimensions of the EORTC QLQ-C30 and the NHP questionnaires did not correlate with urinary and sexual status.
Discussion
The evaluation of the quality of life of prostate cancer patients is essential. However, few studies have concerned the quality of life of patients with localized disease. The impact of treatment is of major concern because, even if patient disease is cured, levels of fonctionning may be impaired and late complications may persist. Certain elderly men might choose treatment with lower long-term survival but with increased chances of remaining sexually potent [29] .
In our study, patients' day-to-day lives do not appear compromised after the association of EBI and BT compared with those of controls. However, four years or more after completion of treatment, patients frequently express urinary and sexual sequelae.
The magnitude of treatment-related sequelae concerning urinary, digestive and sexual status differs considerably when expressed by patients or physicians [30] . Although treatment-related sequelae reported by physicians were abstracted from the charts, they overestimate dysuria and nocturia whereas they underestimate urinary incontinence and pelvic pain after treatment. These findings are in agreement with those of Calais da Silva et al. [31] who reported underestimation of symptoms, such as pain and impotency, by physicans. The latter tend to minimize the expected impact of treatment on quality of life and concentrate on maximizing the duration of survival. In the current debate on the best treatment for localized prostate cancer, patient quality of life must be considered and its evaluation performed by patients and not by physicians who cannot collect reliable subjective information during consultation [4, 15, 31, 32] . The high participation rate among patients and controls, similar to that reported by Litwin et al. [16] , indicates that health-related quality of life evaluation of French elderly men using self-administrated questionnaires is feasible. The high participation rate and the low proportion of missing data among patients and controls also demonstrate the interest and the need of communication on day-to-day difficulties encountered by elderly men. Sexual behavior, for example, was recently the subject of a published comprehensive survey in the United States but the survey did not include data on individuals older than 59 years of age [33] . However, sexual interest is still high in 70-year-old men [29, 34] . As far as sexual disorders are concerned, they are recorded particularly poorly by physicians. Communication between patients and physicians is of great importance; together with complete information about risk of treatment-related sexual sequelae it can help patients to accept the treatment and to return to social life as normally as possible.
While prostate cancer and its treatment do not seem to affect patients' general health-related quality of life, it is not surprising that sexual and urinary disorders are reported more often by patients than by controls. In patients, the major complaints concern sexual activity and interest in sex which are also reported by controls. Urinary incontinence and cystitis are also more frequent in patients than in controls. In patients, urinary status related scores highly correlate with global health status and social functioning scores; on the other hand, there is no correlation between global health status and sexual status scores. Sexual dysfunctioning appears to be better tolerated than urinary sequelae because it has less impact on day-to-day social activities. The impact of these sequelae might be more important in spouses than in patients, a dimension that was not estimated in the study [21] .
The prevalence of treatment-related complications appears, in this series, to be higher than that of most recent published reports [10, 20, 22, [35] [36] [37] . In all but one of these reports, sequelae are reported by physicians rather than by patients. However, our results are in agreement with those of three large population-based studies in which prostate cancer-targeted quality of life was evaluated by patients [14, 16, 38] . Because various questionnaires have been applied and criteria used to evaluate specific sequelae (such as urinary incontinence or sexual dysfunctioning) differ from one study to another, inter-study comparisons must be made with caution. Urinary incontinence is expressed by 40% of the patients treated with the association of BT and EBI. Disorders are rarely considered as severe by patients (9%) and their frequencies are similar to those reported by patients treated with exclusive irradiation [14, 16, 39] . Patients treated with combined BT and EBI report cystitis more frequently than patients treated with EBI [16, 38] although it is reported as mild and patients appear to accept it. This complication can be related to BT which delivers higher dose to urethra. In our experience, patients complain less of digestive disorders than usual reports after EBI [16, 22, 38] . In the Litwin et al. study, including patients treated with EBI, the most common complaints included rectal urgency (30%), crampy abdominal pain (26%), and diarrheoa (11%) [16] . Whilst no comparative study has been made between the association of BT and EBI and exclusive EBI, digestive sequelae appear less important with the combined protocol [10, 37] . When high irradiation dose with sharp gradient beyond the target volume must be given to cancer tissue, the dose is lower when delivered with combined BTand EBI than with exclusive EBI. Also, the dose delivered to adjacent organs and critical tissues, such as rectal tissue, is lower with the former technique. A major decrease in sexual activity is reported by 71% of patients who were sexually active before treatment. Among these, 40% no longer have sexual intercourse. For other patients, however, all areas of sexuality are disturbed after treatment. The association of BT and EBI does not prevent from sexual dysfunction when compared with exclusive EBI, which confirms previous observations [16, 22, 40] . In patients withT!-T 2 disease treated with BTand EBI, with a mean follow-up of three to seven years, the three-year local control rate is satisfactory (86% to 95%) as is the three-year disease-free survival rate (78% to 89%) [10, 11] . In the Brune et al. series which involved 231 patients (83% with T 2 -T 3 disease), the three-year and five-year overall survival rates were 76% and 57%, respectively [41] while, in the Easthman at al. series of 113 patients with Ti-T 2 disease, the 10-year overall survival and event-free survival rates were 58% and 53%, respectively [7] . The association of BT and EBI (with a dose per fraction of 2.4 Gy) is not the standard treatment of localized prostate cancer. Although the technique may appear more agressive, patients express satisfaction with care and report a lesser long-term digestive complication rate. Therefore, this combined radiation therapy can be an alternative to standard EBI in patients with localized prostate cancer.
To assess the exact benefit that can be expected from this particular technique, a randomized controlled trial comparing BT and EBI to exclusive EBI should be undertaken. Patients must be involved in the therapeutic decision which should consider not only expected survival rate but also quality of life. Questionnaires on quality of life bring information to physicians and in particular situations, their use can facilitate their communication with patients. However, they cannot replace the dialogue between the patient, his spouse and the physician who must explain to the former the various complications that may appear as a consequence of treatment [42] .
